Artiva Biotherapeutics to present updated AB-101 AlloNK plus rituximab Sjögren disease data at ISSjD 2026
ARTV•Updated AB-101 data to be presented at ISSjD 2026
Artiva Biotherapeutics flagged updated clinical data for AB-101 with rituximab in Sjögren disease for a future oral presentation on Oct. 1, 2026.
Early results in 11 patients showed strong efficacy signals, supporting the company’s strategy to pair its NK-cell therapy with anti-CD20 antibodies.
The program is positioned for outpatient use, a potential differentiator for adoption and commercial rollout in community rheumatology settings.
Artiva also plans to start a Phase 3 registrational trial of AB-101 in refractory rheumatoid arthritis in the second half of 2026.
